Lobular neoplasia on core‐needle biopsy—Clinical significance
Open Access
- 14 June 2004
- Vol. 101 (2) , 242-250
- https://doi.org/10.1002/cncr.20318
Abstract
BACKGROUND Approximately 25% of all cases of atypical ductal hyperplasia (ADH) diagnosed on core biopsy of the breast are associated with ductal carcinoma in situ (DCIS) or invasive malignancy at the same site. As a result, surgical excision has become the standard of care for patients with ADH. In contrast, because data on the relation between breast malignancy and lobular neoplasia (LN) detected on core biopsy are limited, clinical management of patients with LN remains controversial. The goal of the current study was to determine the incidence of breast carcinoma at sites of core biopsy exhibiting LN compared with sites of core biopsy exhibiting ADH. METHODS The results of 2053 core biopsies were reviewed to identify cases of LN and cases of ADH. Follow-up findings on excisional biopsy were categorized as malignancy (DCIS or invasive malignancy) or no malignancy and were compared between the LN group and the ADH group. Mammograms and medical records were reviewed for patients with atypical findings on core biopsy. RESULTS One hundred six (5.2%) of 2053 biopsy samples exhibited atypia on core biopsy. Among these 106 samples, ADH was found in 49 (46%), LN was found in 45 (42%), and both ADH and LN were found in 12 (12%). Malignant disease was detected on follow-up excisional biopsy in 22% of patients with ADH (9 of 41), 14% of patients with LN (3 of 21), and 33% of patients with both ADH and LN (4 of 12) on core biopsy. In the LN group, two cases of malignant disease were associated with lobular carcinoma in situ, and the third case was associated with atypical lobular hyperplasia. Mammographic and clinical features were unable to distinguish patients with malignant findings on excisional biopsy from patients without malignant findings. CONCLUSIONS Malignant disease was found in a substantial percentage of excisional biopsy samples (14%) following the detection of LN on core biopsy. Thus, like patients with ADH, patients with LN on core biopsy could be considered candidates for surgical excision, which would allow full assessment of breast carcinoma risk and thereby facilitate the planning of prevention strategies. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 38 references indexed in Scilit:
- Lobular Carcinoma In Situ Diagnosed By Core Needle Biopsy: When Should It Be Excised?Laboratory Investigation, 2003
- The Management of Lobular Neoplasia Identified on Percutaneous Core Breast BiopsyThe Breast Journal, 2003
- Lobular Neoplasia in Breast Core Needle Biopsy Specimens Is Not Associated With an Increased Risk of Ductal Carcinoma In Situ or Invasive CarcinomaAmerican Journal of Clinical Pathology, 2002
- Calcifications of Lobular Carcinoma In Situ of the BreastAmerican Journal of Roentgenology, 2001
- Lobular Carcinoma In situ on Core Biopsy—What is the Clinical Significance?Clinical Radiology, 2001
- Routinely available indicators of prognosis in breast cancerBreast Cancer Research and Treatment, 1998
- Biopsy of breast microcalcifications using an 11-gauge directional vacuum-assisted device.American Journal of Roentgenology, 1998
- Stereotactic core-needle biopsy of the breast: a report of the Joint Task Force of the American College of Radiology, American College of Surgeons, and College of American PathologistsCA: A Cancer Journal for Clinicians, 1997
- Risk Factors for Breast Cancer in Women with Proliferative Breast DiseaseNew England Journal of Medicine, 1985
- Lobular carcinoma in situ of the breast Detailed analysis of 99 patients with average follow-up of 24 yearsThe American Journal of Surgical Pathology, 1978